Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Idiopathic Thrombocytopenic Purpura

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Idiopathic Thrombocytopenic Purpura. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2013-000961-36 Sponsor Protocol Number: KB057 Start Date*: 2013-11-15
    Sponsor Name:Kedrion SpA
    Full Title: Tolerability and safety evaluation of the administration of Ig VENA at high infusion rates. Open label phase III study.
    Medical condition: Patients affected by primary or secondary immunodeficiency (ID) or patients affected by Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10054979 Secondary immunodeficiency PT
    16.1 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    16.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005276-14 Sponsor Protocol Number: RGCH004 Start Date*: 2016-12-08
    Sponsor Name:Sykehuset Østfold HF
    Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial.
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002946-13 Sponsor Protocol Number: TRA108062 Start Date*: 2009-07-30
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoi...
    Medical condition: Chronic Idiopathic Thrombocytopenic Purpura Púrpura Trombocitopénica Idiopática Crónica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) FR (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-004347-10 Sponsor Protocol Number: 20080009 Start Date*: 2009-06-17
    Sponsor Name:Amgen Inc
    Full Title: A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Im...
    Medical condition: Thrombocytopenia associated with ITP
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed) PL (Completed) BE (Completed) ES (Completed) HU (Completed) SE (Completed) EE (Completed) IT (Completed) LT (Completed) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002184-17 Sponsor Protocol Number: TRA115450 Start Date*: 2012-02-08
    Sponsor Name:Glaxosmithkline Research and Development Ltd
    Full Title: A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pa...
    Medical condition: To assess the efficacy of eltrombopag, relative to placebo, in achieving platelet counts of ≥ 50 Gi/L, when administered to pediatric subjects with previously treated chronic ITP during the first 1...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001371-20 Sponsor Protocol Number: 200170 Start Date*: 2013-09-06
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag
    Medical condition: Acute myelogenous leukemia & Idiopathic thrombocytopenic purpura (ITP
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000886 Acute myeloid leukemia LLT
    14.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) BE (Completed) GR (Completed) PL (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005918-20 Sponsor Protocol Number: ITP001 Start Date*: 2008-12-23
    Sponsor Name:Rikshospitalet
    Full Title: Rituximab as second line treatment for ITP: A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study. “The RITP study”
    Medical condition: Immune thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019375-30 Sponsor Protocol Number: ALX-0681-2.1/10 Start Date*: 2010-09-07
    Sponsor Name:Ablynx
    Full Title: A Phase II single blind, randomized, placebo controlled trial to study the efficacy and safety of anti-von Willebrand factor Nanobody administered as adjunctive treatment to patients with acquired ...
    Medical condition: Acquired thrombotic thrombocytopenic purpura (TTP)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000470-78 Sponsor Protocol Number: TRA102537 Start Date*: 2006-10-30
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe...
    Medical condition: Idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002478-11 Sponsor Protocol Number: 2.0 Start Date*: 2016-07-19
    Sponsor Name:Medical University of Vienna, Department of Internal medicine I
    Full Title: Very low doses of Rituximab for off-label treatment – a Pilot Trial
    Medical condition: Autoimmune-haemolytic Anemia Antiphospholipid Syndrome Immune-mediated Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000154058 10003825 Autoimmune hemolytic anemia LLT
    20.0 100000157088 10023095 ITP LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004371-19 Sponsor Protocol Number: ARC1779-004 Start Date*: 2007-11-20
    Sponsor Name:Archemix Corp.
    Full Title: A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders
    Medical condition: von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP) in remission, acute TTP, and von Willebrand Disease Type- 2b (vWD-2b).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037563 Purpura thrombopenic thrombotic LLT
    9.1 10047715 Von Willebrand's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005586-21 Sponsor Protocol Number: GMX02 Start Date*: 2011-12-07
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura
    Medical condition: Idiopathic thrombocytopenic purpura.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-005871-92 Sponsor Protocol Number: Sahlgrenska/Hematology/2008:1 Start Date*: 2009-02-05
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion 1 gång/månad under 3 månader hos patie...
    Medical condition: Chronic idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003534-32 Sponsor Protocol Number: MOM-M254-001 Start Date*: 2019-01-03
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10074667 Immune thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) HU (Completed) PL (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000173-65 Sponsor Protocol Number: 20030212 Start Date*: 2005-04-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
    Medical condition: Thrombocytopenia in subjects with Immune Thrombocytopenic Purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000174-31 Sponsor Protocol Number: 20030105 Start Date*: 2005-04-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Spl...
    Medical condition: Thrombocytopenia in subjects with Immune Thrombocytopenic Purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002063-60 Sponsor Protocol Number: PRN1008-018(EFC17093) Start Date*: 2020-11-12
    Sponsor Name:Principia Biopharma, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults...
    Medical condition: Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10074667 Immune thrombocytopenic purpura LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) PL (Ongoing) AT (Completed) NO (Ongoing) FR (Trial now transitioned) HU (Ongoing) IT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000471-14 Sponsor Protocol Number: TRA105325 Start Date*: 2006-06-13
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopa...
    Medical condition: Immune thrombocytopenic purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SE (Completed) DE (Completed) ES (Completed) IE (Completed) NL (Completed) GR (Completed) FR (Completed) SK (Completed) GB (Completed) CZ (Completed) DK (Completed) IT (Completed) FI (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000830-12 Sponsor Protocol Number: E5501-G000-302 Start Date*: 2012-08-28
    Sponsor Name:Eisai Limited
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care...
    Medical condition: Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    16.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    16.1 10005329 - Blood and lymphatic system disorders 10036735 Primary thrombocytopenia LLT
    16.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000831-10 Sponsor Protocol Number: E5501-G000-305 Start Date*: 2012-07-16
    Sponsor Name:Eisai Limited
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, i...
    Medical condition: Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    14.1 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    14.1 10005329 - Blood and lymphatic system disorders 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 09:29:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA